Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leonardo Tomei has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Omalizumab Is Associated With Successful Oral Immunotherapy After Failure in Severe Pediatric Food Allergy

    by Letizia Ciliberti, Simona Barni, Claudia Valleriani, Lucrezia Sarti, Giulia Liccioli, Leonardo Tomei, Gabriele Simonetti, Francesco Catamerò, Mattia Giovannini, R. Sharon Chinthrajah, et al.

  • Visual bias in the clinical history of pediatric cutaneous drug hypersensitivity reactions

    by Giacomo Gagliardi, Leonardo Tomei, Giulia Liccioli, Simona Barni, Mattia Giovannini, Lucrezia Sarti, Benedetta Pessina, Erika Paladini, Anna Ariano, Salvatore Grosso, et al.

    Background: De‐labeling suspected adverse drug hypersensitivity reactions (DHRs) is a critical goal in clinical practice, as misdiagnosed allergies lead to unnecessary medicalization and unwarranted restrictions on available medications. In children, high‐risk factors for DHRs, such as immediate urticaria, often overlap with common viral rashes, complicating risk stratification. This challenge is compounded by caregiver‐reported histories, which can distort symptom timing and severity. This cross‐sectional comparative questionnaire study with a comparison group evaluated how caregivers and pediatric patients visually recognize common drug‐related skin eruptions and whether non‐clinical variables may affect recognition accuracy. Methods: Patients and caregivers referred to the Allergy Units of two tertiary care hospitals for suspected DHRs were included. Questionnaires were offered to caregivers and patients aged 7–17. Participants were divided into two groups: patients with suspected DHRs and subjects without a history of DHRs. Enrolled subjects were asked to recognize pictures of maculopapular, micropapular, and urticaria via a multiple‐choice questionnaire. Results: Data from 405 participants were collected between September 2023 and August 2024. Statistical analysis showed that higher caregiver education and a positive personal history of DHRs and/or urticaria significantly improved recognition accuracy. Nevertheless, nearly half of participants with suspected DHR history misidentified urticaria as micropapular rash. Rash recognition skills did not differ significantly between healthcare and non‐healthcare caregivers. Conclusion: These findings highlight the need for systematic approaches beyond descriptive histories. Integrating non‐clinical factors into diagnostic frameworks could enhance risk stratification and support safer and more effective allergy workup for de‐labeling suspected DHRs in pediatric patients. image

  • Acetylsalicylic acid provocation test as the first step in the diagnostic work‐up of nonsteroidal anti‐inflammatory drugs hypersensitivity reactions in children

    by Leonardo Tomei, Erika Paladini, Giulia Liccioli, Simona Barni, Lucrezia Sarti, Francesco Catamerò, Mattia Giovannini, Francesca Mori

  • Open Access

    Patch Testing in Paediatric Drug Hypersensitivity Reactions: Current Evidence and Clinical Implications

    by Gabriele Simonetti, Francesco Catamerò, Giulia Liccioli, Leonardo Tomei, Simona Barni, Mattia Giovannini, Lucrezia Sarti, Francesca Mori

    Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis. However, its role in paediatric DHRs remains unclear. Available data indicate that PT is safe and particularly useful when drug provocation testing is contraindicated, such as in patients with severe cutaneous adverse reactions. However, diagnostic yield varies considerably among drug classes and clinical phenotypes. Sensitivity is generally low for beta‐lactam and most non–beta‐lactam antibiotics, which limits their standalone value in common exanthematous reactions. Higher positivity rates have been reported for antiepileptic drugs, and PT may help identify the culprit drug and assess its cross‐reactivity. However, evidence supporting the use of nonsteroidal anti‐inflammatory drugs and paracetamol remains scarce. Methodological heterogeneity and limited paediatric‐specific data further constrain this interpretation. Overall, PT should be considered as a complementary diagnostic tool integrated with clinical history and other tests, highlighting the need for standardized protocols and prospective paediatric studies.

  • Open Access

    Health inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission

    by Carolina Grella, Angela Klain, Amelia Licari, Sara Manti, Francesca Mori, Francesca Galletta, Antonio Andrea Senatore, Leonardo Tomei, Michele Miraglia del Giudice, Gian Luigi Marseglia, et al.

    Pediatric anaphylaxis is a rapidly evolving and potentially fatal allergic reaction whose incidence is increasing worldwide, particularly among young children. Despite international guidelines identifying intramuscular epinephrine as the first‐line, life‐saving treatment, significant health inequities persist in the prevention, recognition, and management of pediatric anaphylaxis. This manuscript, developed by the Primary and Secondary Prevention of Allergic Diseases Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP), moves beyond a traditional narrative review by integrating current evidence with a structured policy‐oriented framework. Evidence highlights pronounced socioeconomic, racial, cultural, biological, and geographic inequities influencing disease burden, access to specialist care, prescription and availability of epinephrine autoinjectors (EAIs), training of caregivers and healthcare professionals, and timely epinephrine use in emergency settings. Building on this evidence, we propose a SIAIP‐driven call to action and outline a preliminary national policy framework aimed at reducing inequities through coordinated interventions. Key priorities include equitable access to EAIs, standardized and repeated practical training, school‐based preparedness programs, public awareness initiatives, integration of psychological support, and the development of national monitoring systems. By translating evidence into actionable strategies, this work provides a national perspective that complements existing international recommendations and offers a model for other countries seeking to address disparities in pediatric anaphylaxis care.


  • Open Access

    IgE-Mediated Legume Allergy in Children: Insights from a Single-Center Experience in Italy

    by Beatrice Serra, Simona Barni, Claudia Valleriani, Beatrice Coppadoro, Francesco Catamerò, Letizia Ciliberti, Mattia Giovannini, Giulia Liccioli, Lucrezia Sarti, Leonardo Tomei, et al.

    Background/Objectives: Legume allergy is increasingly recognized as plant-based diets expand and legume proteins are widely used in processed foods. We aimed to characterize the clinical features, sensitization profiles, and management outcomes of IgE-mediated legume allergy in Italian children. Methods: This retrospective single-center study (January 2022–January 2024) included children (p = 0.013) and liver transplantation (21% vs. 2%; p = 0.047). Peanut co-allergy occurred in 25.5%. Among 34 oral food challenges (OFCs), 23.5% were positive, including one case of pea-induced anaphylaxis. Of 16 oral immunotherapy (OIT) protocols initiated, 31.3% reached the full target maintenance dose, 37.5% remained on a lower, partial maintenance dose, and 31.3% were discontinued due to oral allergy syndrome (OAS). Conclusions: Pediatric legume allergy is characterized by early onset, frequent multi-legume involvement, and common co-allergies. In this cohort, pea allergy was associated with the highest proportion of severe reactions. Species-specific differences in severity, patterns of multi-legume involvement, and OIT outcomes should be interpreted cautiously given the limited sample size, while highlighting the need for tailored management and improved risk assessment across legume species.

  • Open Access

    Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study

    by Benedetta Pessina, Camilla Sertori, Simona Barni, Francesco Catamerò, Giulia Liccioli, Erika Paladini, Lucrezia Sarti, Leonardo Tomei, Julia Upton, Claudia Valleriani, et al.

    Introduction: Peanut oral immunotherapy (P-OIT) is an emerging treatment strategy for peanut allergy (PA). Although a standardized pharmaceutical product, Peanut (Arachis hypogaea) Allergen Powder-dnfp, has been approved in several countries, it is not universally available. In such contexts, real-world protocols using readily utilizable peanut products may represent an alternative approach. This study aimed to describe the feasibility, safety, and clinical outcomes of P-OIT using toasted peanuts in a real-world effort in a pediatric population. Methods: This single-center retrospective cohort study enrolled children who initiated P-OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024. Demographic and clinical features, allergy test results, and information about P-OIT were recorded. Desensitization was defined as tolerance of 630 mg of peanut protein (PP). Results: Sixty patients (51.7% male; median age 8.2 years) were included. 22/60 (36.7%) achieved desensitization within a median time of 22.7 months. 21/60 (35%) were still undergoing P-OIT at a median tolerated dose of 100 mg of PP, and 17/60 (28.3%) discontinued treatment, most commonly due to loss to follow-up (44%). At least one adverse reaction occurred in 43/60 (71.7%) patients, predominantly mild and self-limiting (68.3% resolved spontaneously, 39.5% occurred at home). However, 11/60 (18.3%) showed anaphylaxis, and 3/60 (5%) received adrenaline. A reduction in Ara h 2 serum-specific IgE levels compared to the baseline was observed in patients completing escalation (p = 0.03). Conclusions: In this real-world single-center cohort, P-OIT using toasted peanuts was feasible in a subset of patients and was associated predominantly with mild adverse reactions, although systemic reactions were also recorded. Treatment discontinuation and adherence remain relevant challenges. These findings highlight the need for prospective, controlled studies to better define the role, safety profile, and patient selection criteria for food-based P-OIT protocols in settings where standardized products are not available.


  • Increase of post–SARS‐CoV‐2 rashes mimicking penicillin allergy in children with Group A beta‐hemolytic Streptococcus infection: An emerging and challenging issue

    by Francesco Catamerò, Silvia Beretta, Giulia Liccioli, Leonardo Tomei, Gabriele Simonetti, Simona Barni, Mattia Giovannini, Benedetta Pessina, Lucrezia Sarti, Enza D'AUria, et al.

    Background: Group A beta‐hemolytic Streptococcus (GABHS) infections have surged globally in the post–SARS‐CoV‐2 era, coinciding with an increase in the number of children referred for suspected delayed hypersensitivity to penicillin administered during acute infection. GABHS‐related rashes may resemble non‐immediate drug reactions, complicating diagnosis, and contributing to inappropriate penicillin allergy diagnosis. Methods: Medical charts from patients followed at Allergy Unit of Meyer Children's Hospital IRCCS, Florence, Italy and Pediatric Department of “Vittore Buzzi” Children's Hospital, Milan, Italy, who underwent a penicillin drug provocation test (DPTs) between August 2015 and August 2025, were retrospectively reviewed. Only patients with documented, laboratory‐confirmed GABHS infections treated with penicillin were included. Results: Seventy patients treated with penicillin for concomitant GABHS infections that developed rash during therapy were included. The median time to rash insurgence was after 7 days of treatment (IQR = 4 days). Maculopapular rash was the most frequent (43/70, 61.4%) followed by urticarial rash in the remaining cases (27/70, 38.6%). No systemic reactions were reported. DPTs were negative in 63/70 (90%) patients, with only mild cutaneous reactions in the remaining cases, all manageable with antihistamines. All patients who experienced a positive DPT initially reported an urticarial rash as the reason for referral, whereas all patients with a history of maculopapular rash as the index reaction showed a negative DPT. Conclusion: GABHS may be associated with a rash that mimics delayed penicillin allergy, which is excluded by negative DPTs.


  • Open Access

    Hazelnut oral immunotherapy in children: An Italian single‐center retrospective cohort study

    by Simona Barni, Benedetta Pessina, Serena Della Femina, Francesco Catamerò, Claudia Valleriani, Mattia Giovannini, Giulia Liccioli, Lucrezia Sarti, Leonardo Tomei, Francesca Mori

    Introduction: Hazelnut oral immunotherapy (H‐OIT) is a promising treatment for hazelnut allergy (HA). The aim of this study was to assess the safety and efficacy of H‐OIT in a pediatric population, while describing its clinical and allergy characteristics. Methods: Children undergoing H‐OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024 were enrolled. Demographic and clinical features, allergy test results and information on H‐OIT were recorded. Results: 124 patients (58.1% male; median age 8.5 years) were enrolled, 73 (58.9%) aged p < 0.001) and Cor a 14 IgE levels ( p = 0.004) were observed. A positive family history of atopy was associated with lower odds of completing H‐OIT (odds ratio 0.221, 95% confidence interval 0.055–0.895, p = 0.034). Conclusion: H‐OIT may be an effective treatment option for children with HA despite the high discontinuation rate. One quarter of patients remained on a lower, partial maintenance dose. Although the overall safety profile of H‐OIT seems acceptable, anaphylactic events represent a significant burden for families and must be carefully considered when weighing the risks and benefits of OIT.